**S&F References**

Intro/descriptive epi

(1995, Ades*, et al* 2014, Allemani*, et al* 2015, Barbui*, et al* 2011, Bochtler*, et al* 2015, Campbell and Green 2006, Chen*, et al* 2010, Cogle 2015, Craig*, et al* 2012, Dameshek 1951, Dohner*, et al* 2015, Dores*, et al* 2012, Ferrara and Schiffer 2013, Fritz*, et al* 2000, Gangatharan*, et al* 2013, Giagounidis and Haase 2013, Goldberg*, et al* 2010, Greenberg*, et al* 1997, Greenberg*, et al* 2012, Jaffe*, et al* 2001, James*, et al* 2005, Kadia*, et al* 2015, Kipps and Huan-You, Kralovics*, et al* 2005, Lehmann*, et al* 2011, Lichtman, Lundberg*, et al* 2014, Maynadie*, et al* 2011, McQuilten*, et al* 2014, Melo and Barnes 2007, Meyer and Levine 2014, Morton*, et al* 2006, Network 2013, Ortmann*, et al* 2015, Park*, et al* 2011, Passamonti*, et al* 2010, Passamonti*, et al* 2008, Patel*, et al* 2012, Polednak 2011, Polednak 2013, Rollig*, et al* 2011, Rollison*, et al* 2008, Sant*, et al* 2010, Sant*, et al* 2014, Schlenk*, et al* 2008, Shizuru*, et al* 2005, Shlush and Minden 2015, Siegel*, et al* 2016, Smith*, et al* 2011)(Smith*, et al* 2009, Sokal*, et al* 1984, Swerdlow*, et al* 2008, Tefferi and Pardanani 2015, Tenen 2003, Vardiman 2012, Vardiman*, et al* 2002, Vardiman*, et al* 2009, Voso*, et al* 2013)

Ades, L., Itzykson, R. & Fenaux, P. (2014) Myelodysplastic syndromes. *Lancet,* **383,** 2239-2252.

Allemani, C., Weir, H.K., Carreira, H., Harewood, R., Spika, D., Wang, X.S., Bannon, F., Ahn, J.V., Johnson, C.J., Bonaventure, A., Marcos-Gragera, R., Stiller, C., Azevedo e Silva, G., Chen, W.Q., Ogunbiyi, O.J., Rachet, B., Soeberg, M.J., You, H., Matsuda, T., Bielska-Lasota, M., Storm, H., Tucker, T.C. & Coleman, M.P. (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet,* **385,** 977-1010.

Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E.S., Randi, M.L., Bertozzi, I., Marino, F., Vannucchi, A.M., Antonioli, E., Carrai, V., Gisslinger, H., Buxhofer-Ausch, V., Mullauer, L., Carobbio, A., Gianatti, A., Gangat, N., Hanson, C.A. & Tefferi, A. (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol,* **29,** 3179-3184.

Bochtler, T., Frohling, S. & Kramer, A. (2015) Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. *Leukemia,* **29,** 1243-1252.

Campbell, P.J. & Green, A.R. (2006) The myeloproliferative disorders. *N Engl J Med,* **355,** 2452-2466.

Chen, J., Odenike, O. & Rowley, J.D. (2010) Leukaemogenesis: more than mutant genes. *Nat Rev Cancer,* **10,** 23-36.

Cogle, C.R. (2015) Incidence and Burden of the Myelodysplastic Syndromes. *Curr Hematol Malig Rep,* **10,** 272-281.

Craig, B.M., Rollison, D.E., List, A.F. & Cogle, C.R. (2012) Underreporting of myeloid malignancies by United States cancer registries. *Cancer Epidemiol Biomarkers Prev,* **21,** 474-481.

Dameshek, W. (1951) Some speculations on the myeloproliferative syndromes. *Blood,* **6,** 372-375.

Dohner, H., Weisdorf, D.J. & Bloomfield, C.D. (2015) Acute Myeloid Leukemia. *N Engl J Med,* **373,** 1136-1152.

Dores, G.M., Devesa, S.S., Curtis, R.E., Linet, M.S. & Morton, L.M. (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. *Blood,* **119,** 34-43.

Gruppo Italiano Studio Policitemia. (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. *Ann Intern Med,* **123,** 656-664.

Ferrara, F. & Schiffer, C.A. (2013) Acute myeloid leukaemia in adults. *Lancet,* **381,** 484-495.

Fritz, A., Percy, C., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D.M. & Whelan, S. (eds.) (2000) *International Classification of Diseases for Oncology.* World Health Organization, Geneva, Switzerland.

Gangatharan, S.A., Grove, C.S., P'ng, S., O'Reilly, J., Joske, D., Leahy, M.F., Threlfall, T. & Wright, M.P. (2013) Acute myeloid leukaemia in Western Australia 1991-2005: a retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome. *Intern Med J,* **43,** 903-911.

Giagounidis, A. & Haase, D. (2013) Morphology, cytogenetics and classification of MDS. *Best Pract Res Clin Haematol,* **26,** 337-353.

Goldberg, S.L., Chen, E., Corral, M., Guo, A., Mody-Patel, N., Pecora, A.L. & Laouri, M. (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. *J Clin Oncol,* **28,** 2847-2852.

Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood,* **89,** 2079-2088.

Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. *Blood,* **120,** 2454-2465.

Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (eds.) (2001) *World Health Organization classification of tumours. Pathology and genetics of haematopoietic and lymphoid tissues.* IARC Press, Lyon.

James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature,* **434,** 1144-1148.

Kadia, T.M., Ravandi, F., Cortes, J. & Kantarjian, H. (2015) Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. *JAMA Oncol,* **1,** 820-828.

Kipps, T.J. & Huan-You, W. Classification of malignant lymphoid disorders In: *Williams Hematatology*.

Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med,* **352,** 1779-1790.

Lehmann, S., Ravn, A., Carlsson, L., Antunovic, P., Deneberg, S., Mollgard, L., Derolf, A.R., Stockelberg, D., Tidefelt, U., Wahlin, A., Wennstrom, L., Hoglund, M. & Juliusson, G. (2011) Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. *Leukemia,* **25,** 1128-1134.

Lichtman, M.A. Classification and clinical manifestations of the clonal myeloid disorders. In: *Willliams Hematology*.

Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., Beisel, C., Kralovics, R. & Skoda, R.C. (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood,* **123,** 2220-2228.

Maynadie, M., Girodon, F., Manivet-Janoray, I., Mounier, M., Mugneret, F., Bailly, F., Favre, B., Caillot, D., Petrella, T., Flesch, M. & Carli, P.M. (2011) Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). *Haematologica,* **96,** 55-61.

McQuilten, Z.K., Wood, E.M., Polizzotto, M.N., Campbell, L.J., Wall, M., Curtis, D.J., Farrugia, H., McNeil, J.J. & Sundararajan, V. (2014) Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. *Cancer,* **120,** 1686-1694.

Melo, J.V. & Barnes, D.J. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. *Nat Rev Cancer,* **7,** 441-453.

Meyer, S.C. & Levine, R.L. (2014) Translational implications of somatic genomics in acute myeloid leukaemia. *Lancet Oncol,* **15,** e382-394.

Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. & Linet, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood,* **107,** 265-276.

Network, T.C.G.A.R. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med,* **368,** 2059-2074.

Ortmann, C.A., Kent, D.G., Nangalia, J., Silber, Y., Wedge, D.C., Grinfeld, J., Baxter, E.J., Massie, C.E., Papaemmanuil, E., Menon, S., Godfrey, A.L., Dimitropoulou, D., Guglielmelli, P., Bellosillo, B., Besses, C., Dohner, K., Harrison, C.N., Vassiliou, G.S., Vannucchi, A., Campbell, P.J. & Green, A.R. (2015) Effect of mutation order on myeloproliferative neoplasms. *N Engl J Med,* **372,** 601-612.

Park, J.H., Qiao, B., Panageas, K.S., Schymura, M.J., Jurcic, J.G., Rosenblat, T.L., Altman, J.K., Douer, D., Rowe, J.M. & Tallman, M.S. (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. *Blood,* **118,** 1248-1254.

Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood,* **115,** 1703-1708.

Passamonti, F., Rumi, E., Arcaini, L., Boveri, E., Elena, C., Pietra, D., Boggi, S., Astori, C., Bernasconi, P., Varettoni, M., Brusamolino, E., Pascutto, C. & Lazzarino, M. (2008) Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. *Haematologica,* **93,** 1645-1651.

Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med,* **366,** 1079-1089.

Polednak, A.P. (2011) US death rates from myeloproliferative neoplasms, and implications for cancer surveillance. *J Registry Manag,* **38,** 87-92.

Polednak, A.P. (2013) Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. *Cancer Epidemiol,* **37,** 569-574.

Rollig, C., Bornhauser, M., Thiede, C., Taube, F., Kramer, M., Mohr, B., Aulitzky, W., Bodenstein, H., Tischler, H.J., Stuhlmann, R., Schuler, U., Stolzel, F., von Bonin, M., Wandt, H., Schafer-Eckart, K., Schaich, M. & Ehninger, G. (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. *J Clin Oncol,* **29,** 2758-2765.

Rollison, D.E., Howlader, N., Smith, M.T., Strom, S.S., Merritt, W.D., Ries, L.A., Edwards, B.K. & List, A.F. (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. *Blood,* **112,** 45-52.

Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadie, M., Simonetti, A., Lutz, J.M., Berrino, F. & Group, H.W. (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood,* **116,** 3724-3734.

Sant, M., Minicozzi, P., Mounier, M., Anderson, L.A., Brenner, H., Holleczek, B., Marcos-Gragera, R., Maynadie, M., Monnereau, A., Osca-Gelis, G., Visser, O. & De Angelis, R. (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. *Lancet Oncol,* **15,** 931-942.

Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N Engl J Med,* **358,** 1909-1918.

Shizuru, J.A., Negrin, R.S. & Weissman, I.L. (2005) Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. *Annu Rev Med,* **56,** 509-538.

Shlush, L.I. & Minden, M.D. (2015) Preleukemia: the normal side of cancer. *Curr Opin Hematol,* **22,** 77-84.

Siegel, R.L., Miller, K.D. & Jemal, A. (2016) Cancer statistics, 2016. *CA Cancer J Clin,* **66,** 7-30.

Smith, A., Howell, D., Patmore, R., Jack, A. & Roman, E. (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. *Br J Cancer,* **105,** 1684-1692.

Smith, A., Roman, E., Howell, D., Jones, R., Patmore, R., Jack, A. & Haematological Malignancy Research, N. (2009) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. *Br J Haematol,* **148,** 739-753.

Sokal, J.E., Cox, E.B., Baccarani, M., Tura, S., Gomez, G.A., Robertson, J.E., Tso, C.Y., Braun, T.J., Clarkson, B.D., Cervantes, F. & et al. (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. *Blood,* **63,** 789-799.

Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds.) (2008) *WHO classification of tumours of haematopoietic and lymphoid tissues.* International Agency for Research on Cancer, Lyon.

Tefferi, A. & Pardanani, A. (2015) Myeloproliferative Neoplasms: A Contemporary Review. *JAMA Oncol,* **1,** 97-105.

Tenen, D.G. (2003) Disruption of differentiation in human cancer: AML shows the way. *Nat Rev Cancer,* **3,** 89-101.

Vardiman, J. (2012) The classification of MDS: from FAB to WHO and beyond. *Leuk Res,* **36,** 1453-1458.

Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood,* **100,** 2292-2302.

Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood,* **114,** 937-951.

Voso, M.T., Fenu, S., Latagliata, R., Buccisano, F., Piciocchi, A., Aloe-Spiriti, M.A., Breccia, M., Criscuolo, M., Andriani, A., Mancini, S., Niscola, P., Naso, V., Nobile, C., Piccioni, A.L., D'Andrea, M., D'Addosio, A., Leone, G. & Venditti, A. (2013) Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. *J Clin Oncol,* **31,** 2671-2677.